Iron in chronic brain disorders: Imaging and neurotherapeutic implications

SummaryIron is important for brain oxygen transport, electron transfer, neurotransmitter synthesis, and myelin production. Though iron deposition has been observed in the brain with normal aging, increased iron has also been shown in many chronic neurological disorders including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. In vitro studies have demonstrated that excessive iron can lead to free radical production, which can promote neurotoxicity. However, the link between observed iron deposition and pathological processes underlying various diseases of the brain is not well understood. It is not known whether excessive in vivo iron directly contributes to tissue damage or is solely an epiphenomenon. In this article, we focus on the imaging of brain iron and the underlying physiology and metabolism relating to iron deposition. We conclude with a discussion of the potential implications of iron-related toxicity to neurotherapeutic development.

[1]  A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators. , 1996, Stroke.

[2]  Christian Gluud,et al.  Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.

[3]  W Craelius,et al.  Iron deposits surrounding multiple sclerosis plaques. , 1982, Archives of pathology & laboratory medicine.

[4]  A. Koeppen,et al.  The pathogenesis of superficial siderosis of the central nervous system , 1993, Annals of neurology.

[5]  R. Brooks,et al.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.

[6]  L. A. Hansen,et al.  Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the anti-oxidant, butylated hydroxyanisole , 1995, Journal of Neuroimmunology.

[7]  M. Vérin,et al.  Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. , 2002, Journal of hepatology.

[8]  R. Bakshi,et al.  MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images , 1998, Neuroradiology.

[9]  M. Cotter,et al.  Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. , 1995, The Journal of clinical investigation.

[10]  M. Savoiardo Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging , 2003, Neurological Sciences.

[11]  S. LeVine,et al.  Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice , 1998, Journal of Neuroimmunology.

[12]  G A Johnson,et al.  MRI of brain iron. , 1986, AJR. American journal of roentgenology.

[13]  T. Kawanami,et al.  Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[14]  E. Haacke,et al.  Imaging iron stores in the brain using magnetic resonance imaging. , 2005, Magnetic resonance imaging.

[15]  S. LeVine,et al.  Hemeoxygenase-1 in SJL mice with experimental allergic encephalomyelitis , 2003 .

[16]  S. Benkovic,et al.  Isoforms of ferritin have a specific cellular distribution in the brain , 1994, Journal of neuroscience research.

[17]  P. Riederer,et al.  Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? , 1989, Acta neurologica Scandinavica. Supplementum.

[18]  M. Argyropoulou,et al.  T2 relaxation rate of basal ganglia and cortex in patients with β-thalassaemia major , 2001 .

[19]  D. Richardson Novel Chelators for Central Nervous System Disorders That Involve Alterations in the Metabolism of Iron and Other Metal Ions , 2004, Annals of the New York Academy of Sciences.

[20]  J. Gutteridge,et al.  Iron and oxygen radicals in brain , 1992, Annals of neurology.

[21]  John F Schenck,et al.  Magnetic resonance imaging of brain iron , 2003, Journal of the Neurological Sciences.

[22]  D. Calne The free radical hypothesis in idiopathic parkinsonism: Evidence against it , 1992, Annals of neurology.

[23]  P. Doherty,et al.  Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent , 1984, The Journal of experimental medicine.

[24]  H. Schipper,et al.  Proinflammatory cytokines promote glial heme oxygenase‐1 expression and mitochondrial iron deposition: implications for multiple sclerosis , 2001, Journal of neurochemistry.

[25]  R. Gold,et al.  The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis , 2004, Clinical and experimental immunology.

[26]  P. Riederer,et al.  Potential sources of increased iron in the substantia nigra of parkinsonian patients. , 2006, Journal of neural transmission. Supplementum.

[27]  W. Rayens,et al.  Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys , 2007, Neurobiology of Aging.

[28]  D. Berg,et al.  In vivo detection of iron and neuromelanin by transcranial sonography – a new approach for early detection of substantia nigra damage , 2006, Journal of Neural Transmission.

[29]  Subramanian Rajagopalan,et al.  Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo A Novel Therapy for Parkinson's Disease , 2003, Neuron.

[30]  A. Blamire,et al.  Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. , 2005, Archives of neurology.

[31]  M. Youdim,et al.  Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.

[32]  P. Mantyh,et al.  Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β‐Amyloid Peptide , 1993, Journal of neurochemistry.

[33]  G. Tocco,et al.  Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. , 1997, Cellular immunology.

[34]  H. Miyajima,et al.  Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate , 2007, Brain and Development.

[35]  Glyn Johnson,et al.  Magnetic field correlation imaging , 2006, Magnetic resonance in medicine.

[36]  Yi Ai,et al.  Correlation of R2 with total iron concentration in the brains of rhesus monkeys , 2005, Journal of magnetic resonance imaging : JMRI.

[37]  J. Eaton,et al.  Glycochelates and the etiology of diabetic peripheral neuropathy. , 2000, Free radical biology & medicine.

[38]  J. Wilson,et al.  Use of allopurinol and deferoxamine in cellular protection during ischemia. , 1992, Surgical neurology.

[39]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[40]  S. Mandel,et al.  Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration , 2001, Journal of neurochemistry.

[41]  R. A. Knight,et al.  ASSESSMENT OF RELATIVE BRAIN IRON CONCENTRATIONS USING T-2-WEIGHTED AND T-2(ASTERISK)-WEIGHTED MRI AT 3-TESLA , 1994 .

[42]  P. Harrison,et al.  Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. , 1992, The Biochemical journal.

[43]  P. Crack,et al.  Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron‐mediated hydrogen peroxide toxicity , 2006, Journal of neuroscience research.

[44]  J. Gitlin,et al.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Bakshi,et al.  FLAIR MRI of striatonigral degeneration , 2001, Neurology.

[46]  Steven M LeVine,et al.  Iron deposits in multiple sclerosis and Alzheimer's disease brains , 1997, Brain Research.

[47]  W. D. Ehmann,et al.  Brain trace elements in Alzheimer's disease. , 1986, Neurotoxicology.

[48]  R. Medda,et al.  The physiopathological significance of ceruloplasmin. A possible therapeutic approach. , 2000, Biochemical pharmacology.

[49]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[50]  P. Riederer,et al.  The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[51]  Jim Mintz,et al.  Brain ferritin iron may influence age- and gender-related risks of neurodegeneration , 2007, Neurobiology of Aging.

[52]  C. Morris,et al.  Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease , 2001, Nature Genetics.

[53]  M. I. Argyropoulou,et al.  MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease , 2005, Journal of Neurology.

[54]  E. Morgan,et al.  Evidence for low molecular weight, non‐transferrin‐bound iron in rat brain and cerebrospinal fluid , 1998, Journal of neuroscience research.

[55]  G. Sawle,et al.  Palatal tremor and cognitive decline in neuroferritinopathy , 2002, Journal of neurology, neurosurgery, and psychiatry.

[56]  R A Knight,et al.  MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. , 1999, Radiology.

[57]  S. LeVine,et al.  Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. , 2003, Multiple sclerosis.

[58]  Rabi Tawil,et al.  Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. , 2005, Journal of neuropathology and experimental neurology.

[59]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[60]  C. W. Tjoa,et al.  MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis , 2005, Journal of the Neurological Sciences.

[61]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[62]  A. Moss,et al.  Idebenone for treatment of Friedreich’s ataxia? , 2003, Neurology.

[63]  E. Haley High-dose tirilazad for acute stroke (RANTTAS II). RANTTAS II Investigators. , 1998, Stroke.

[64]  J. R. Mitchell,et al.  Deep grey matter `black T2` on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis , 2007, Multiple sclerosis.

[65]  M. Yorubulut,et al.  T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. , 2004, Neurology India.

[66]  S W Atlas,et al.  Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. , 1991, Radiology.

[67]  J. Keaney,et al.  Iron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease , 2001, Circulation.

[68]  R. Crichton,et al.  Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. , 2002, Journal of inorganic biochemistry.

[69]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[70]  G. Bartzokis,et al.  In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. , 2000, Archives of general psychiatry.

[71]  Hisashi Tanaka,et al.  Determination of transverse relaxation rate for estimating iron deposits in central nervous system , 2005, Neuroscience Research.

[72]  Jim Mintz,et al.  Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases , 2005, Alzheimer's & Dementia.

[73]  David Katz,et al.  The relation between brain iron and NMR relaxation times: An in vitro study , 1996, Magnetic resonance in medicine.

[74]  M. Récasens,et al.  A transient treatment of hippocampal neurons with alpha-tocopherol induces a long-lasting protection against oxidative damage via a genomic action. , 2005, Free radical biology & medicine.

[75]  Alberto Gatti,et al.  The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[76]  G. Cohen,et al.  Oxidative Stress, Mitochondrial Respiration, and Parkinson's Disease , 2000, Annals of the New York Academy of Sciences.

[77]  W. Bradley,et al.  Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. , 1988, Radiology.

[78]  S. LeVine,et al.  Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. , 1998, Life sciences.

[79]  P. Ponka Hereditary Causes of Disturbed Iron Homeostasis in the Central Nervous System , 2004, Annals of the New York Academy of Sciences.

[80]  M. Barcikowska,et al.  Iron in parkinsonian and control substantia nigra—A mössbauer spectroscopy study , 1996, Movement disorders : official journal of the Movement Disorder Society.

[81]  D. Birchall,et al.  Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. , 2006, Brain : a journal of neurology.

[82]  R. Hider,et al.  The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy , 2005, British journal of pharmacology.

[83]  C. Marsden,et al.  INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.

[84]  Shawn K. Westaway,et al.  A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome , 2001, Nature Genetics.

[85]  A. Mackay,et al.  In vivo measurement of T2 distributions and water contents in normal human brain , 1997, Magnetic resonance in medicine.

[86]  J. Eaton,et al.  Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[87]  Andrew J Wheaton,et al.  T2ρ‐weighted contrast in MR images of the human brain , 2004, Magnetic resonance in medicine.

[88]  R. Ordidge,et al.  Assessment of relative brain iron concentrations using T2‐weighted and T2*‐weighted MRI at 3 Tesla , 1994, Magnetic resonance in medicine.

[89]  J. Gitlin,et al.  Use of desferrioxamine in the treatment of aceruloplasminemia , 1997, Annals of neurology.

[90]  J. Pujol,et al.  Biological significance of iron-related magnetic resonance imaging changes in the brain. , 1992, Archives of neurology.

[91]  D. Ben-shachar,et al.  The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.

[92]  E. Hall Novel inhibitors of iron‐dependent lipid peroxidation for neurodegenerative disorders , 1992, Annals of neurology.

[93]  L. Kappelle,et al.  Inhibition of Iron-Dependent and Ischemia-Induced Brain Damage by the α-Tocopherol Analogue MDL 74,722 , 1999, Experimental Neurology.

[94]  P. Dash,et al.  Deferoxamine improves spatial memory performance following experimental brain injury in rats , 1996, Brain Research.

[95]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[96]  B. Drayer,et al.  Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? , 1987, AJR. American journal of roentgenology.

[97]  W. D. Ehmann,et al.  Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. , 1998, Neurotoxicology.

[98]  S. Lynch,et al.  A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. , 2000, Cellular and molecular biology.

[99]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[100]  D. Patel,et al.  Desmethyl tirilazad improves neurologic function after hypoxic ischemic brain injury in piglets , 2000, Critical care medicine.

[101]  R. Uitti,et al.  Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[102]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[103]  R. Hauser,et al.  Magnetic Resonance Imaging of Corticobasal Degeneration , 1996, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[104]  R. Bakshi,et al.  T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. , 2002, Archives of neurology.

[105]  J. Gitlin,et al.  Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. , 1998, The American journal of clinical nutrition.

[106]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[107]  G. Bartzokis,et al.  MR evaluation of age-related increase of brain iron in young adult and older normal males. , 1997, Magnetic resonance imaging.

[108]  S. Robinson,et al.  β-amyloid helps to protect neurons from oxidative stress , 2000, Neurobiology of Aging.

[109]  J. Fernández-Real,et al.  Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. , 2002, Diabetes care.

[110]  H. Rowley,et al.  Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. , 2006, AJNR. American journal of neuroradiology.

[111]  D. McLachlan,et al.  Intramuscular desferrioxamine in patients with Alzheimer's disease , 1991, The Lancet.

[112]  E. Unger,et al.  Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted MR images. , 1994, Radiology.

[113]  T. Rouault,et al.  Iron on the brain , 2001, Nature Genetics.

[114]  T. Montine,et al.  Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[115]  K. Krabbe,et al.  Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[116]  G. Perry,et al.  Oxidative Stress and Redox‐Active Iron in Alzheimer's Disease , 2004, Annals of the New York Academy of Sciences.

[117]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[118]  R. Llinas,et al.  Superficial siderosis: a case report and review of the literature , 2007, Nature Clinical Practice Neurology.

[119]  Christine D. Dijkstra,et al.  Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats , 1995, Journal of Neuroimmunology.

[120]  Mark Hallett,et al.  Increased iron in the dentate nucleus of patients with Friedreich's ataxia , 1999, Annals of neurology.

[121]  Ruitian Song,et al.  Echo-spacing optimization for the simultaneous measurement of reversible (R2') and irreversible (R2) transverse relaxation rates. , 2007, Magnetic resonance imaging.

[122]  P. Jenner Oxidative stress as a cause of Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.

[123]  D. Jiang,et al.  Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice , 2005, Journal of Neural Transmission.

[124]  W H Oldendorf,et al.  Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores , 1993, Magnetic resonance in medicine.

[125]  Ashley I. Bush,et al.  Redox-active iron mediates amyloid-β toxicity , 2001 .

[126]  K. Uğurbil,et al.  Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts , 2007, Movement disorders : official journal of the Movement Disorder Society.

[127]  M. Cotter,et al.  Effects of an extracellular metal chelator on neurovascular function in diabetic rats , 2001, Diabetologia.

[128]  C. Morris,et al.  Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. , 1992, The Biochemical journal.

[129]  F W Wehrli,et al.  Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate. , 1996, Journal of magnetic resonance. Series B.

[130]  Mark A. Smith,et al.  Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance , 2006, Neuroscience Letters.

[131]  M. Youdim,et al.  Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion , 2005, Journal of neurochemistry.

[132]  Daniela Berg,et al.  Iron metabolism in Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[133]  Ya Ke,et al.  Iron misregulation in the brain: a primary cause of neurodegenerative disorders , 2003, The Lancet Neurology.

[134]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[135]  M. Nahata,et al.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. , 2000, Drug safety.

[136]  J. Koh,et al.  The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human β-amyloid precursor protein transgenic mice , 2004, Neurobiology of Aging.

[137]  S. Chaturvedi Clinical trials and financial reimbursement. , 1998, Stroke.

[138]  Rohit Bakshi,et al.  Magnetic Resonance Imaging of Iron Deposition in Neurological Disorders , 2006, Topics in magnetic resonance imaging : TMRI.

[139]  H. Schipper Heme Oxygenase‐1: Transducer of Pathological Brain Iron Sequestration under Oxidative Stress , 2004, Annals of the New York Academy of Sciences.

[140]  L. Zecca,et al.  Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability , 2006, Journal of Neural Transmission.

[141]  C. Marsden,et al.  Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.

[142]  V. Vassiliev,et al.  Ceruloplasmin in neurodegenerative diseases , 2005, Brain Research Reviews.

[143]  J. Reichenbach,et al.  Theory and application of static field inhomogeneity effects in gradient‐echo imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[144]  D. Berg,et al.  The basal ganglia in haemochromatosis , 2000, Neuroradiology.

[145]  E. Hall,et al.  Dextran-coupled deferoxamine improves outcome in a murine model of head injury. , 1992, Journal of neurotrauma.

[146]  P. Burger,et al.  MR detection of brain iron. , 1993, AJNR. American journal of neuroradiology.

[147]  G. Bartzokis,et al.  MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. , 2000, Cellular and molecular biology.

[148]  Rohit Bakshi,et al.  Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. , 2005, Archives of neurology.

[149]  D. Bourdette,et al.  Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[150]  P. Doherty,et al.  Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen , 1988, Journal of Neuroimmunology.

[151]  J. Connor,et al.  Relationship of iron to oligodendrocytes and myelination. , 1996, Glia.

[152]  M. Argyropoulou,et al.  T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. , 2001, The British journal of radiology.

[153]  C. Levenson Iron and Parkinson's disease: chelators to the rescue? , 2003, Nutrition reviews.

[154]  E. Shezen,et al.  Oral administration of the oxidant-scavenger N-acetyl-l-cysteine inhibits acute experimental autoimmune encephalomyelitis , 1994, Journal of Neuroimmunology.

[155]  R. Chanderbhan,et al.  Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine. , 1992, Free radical biology & medicine.

[156]  M. Youdim,et al.  Nutritional Iron Deprivation Attenuates Kainate‐Induced Neurotoxicity in Rats: Implications for Involvement of Iron in Neurodegeneration , 2004, Annals of the New York Academy of Sciences.

[157]  Raffaella Mariani,et al.  MR imaging of cerebral cortical involvement in aceruloplasminemia. , 2005, AJNR. American journal of neuroradiology.

[158]  Jim Mintz,et al.  In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI , 1994, Biological Psychiatry.

[159]  T. Montine,et al.  Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from alzheimer's disease patients , 2007, Magnetic resonance in medicine.

[160]  J. Andersen Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? , 2001, Novartis Foundation symposium.

[161]  R. Fariello,et al.  A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease , 2006, Neurology.

[162]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[163]  P. Kloetzel,et al.  Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.

[164]  R. Martins,et al.  Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. , 2006, AJNR. American journal of neuroradiology.

[165]  C. Morris,et al.  Brain iron homeostasis. , 1992, Journal of inorganic biochemistry.

[166]  R. Bakshi,et al.  Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis , 2006, Multiple sclerosis.

[167]  J. Pickard,et al.  A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. , 1999, Journal of neurosurgery.

[168]  L. Beckman,et al.  Transferrin C2, metal binding and Alzheimer's disease , 1998, Neuroreport.

[169]  K. Pantopoulos Iron Metabolism and the IRE/IRP Regulatory System: An Update , 2004, Annals of the New York Academy of Sciences.

[170]  John F. Schenck,et al.  Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths , 1995, Journal of the Neurological Sciences.

[171]  J. Connor,et al.  Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease , 1992, Journal of neuroscience research.

[172]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[173]  R. Bakshi,et al.  T1‐ and T2‐Based MRI Measures of Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis , 2007, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[174]  J. Connor,et al.  Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains , 1990, Journal of neuroscience research.

[175]  C. Olanow,et al.  Oxidative stress and the pathogenesis of Parkinson's disease , 1996, Neurology.

[176]  R. Henkelman,et al.  T2 values in the human brain: comparison with quantitative assays of iron and ferritin. , 1989, Radiology.

[177]  R. Shin,et al.  A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated τ of Alzheimer’s disease , 2003, Brain Research.

[178]  M. Núñez,et al.  Antioxidant responses of cortex neurons to iron loading. , 2006, Biological research.

[179]  R Bakshi,et al.  MRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation , 2000, Neuroreport.

[180]  J. Connor,et al.  Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.

[181]  S. Hayflick Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase–associated neurodegeneration is the name . . . , 2003, Current opinion in pediatrics.

[182]  H. Fenton,et al.  LXXIII.—Oxidation of tartaric acid in presence of iron , 1894 .

[183]  Neha Singh,et al.  Advances in the treatment of Parkinson's disease , 2007, Progress in Neurobiology.

[184]  F. Foury,et al.  A non-essential function for yeast frataxin in iron-sulfur cluster assembly. , 2002, Human molecular genetics.

[185]  E M Haacke,et al.  An MRI method for measuring T2 in the presence of static and RF magnetic field Inhomogeneities , 1997, Magnetic resonance in medicine.